AIMMUNE THERAPEUTICS, INC. (AIMT) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Conditions
On November 14, 2016, Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2016 and its financial position as of September 30, 2016. The full text of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, regardless of any general incorporation language in the filing unless specifically stated so therein.
Item 9.01Financial Statements and Exhibits.
Reference is made to the Exhibit Index attached hereto.
About AIMMUNE THERAPEUTICS, INC. (AIMT)
